Abstract
Goldin et al were the first to document the important modulating effects of citrovorum factor rescue in the treatment of murine leukaemia by methotrexate (1). The notion of “methotrexate rescue” programmes was pioneered clinically by Djerassi et al in the late 1960s (2). The scientific basis for the prevention of methotrexate toxicity by citrovorum factor rescue, without major reduction of antitumour effects, has been the subject of several clinical and laboratory studies during the last few years (3,4).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Goldin A., Venditti J. M., Kline I., Mantel N.: Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plue citrovorum factor. Nature: 1548–1550, 1966.
Djerassi I., Abir E., Roger G. L.: Long term remission in childhood acute leukaemia: use of infrequent infusion of methotrexate; supportive rate of platelet transfusions and citrovorum factor. Clin Pediats (5): 502–509, 1966.
Pinedo H. M., Zaharko D. S., Ball J. M., Chabner B. A.: The reversal of methotrexate cytotoxicity to bone marrow cells by leucovorin and nucleosides. Cancer Res (36): 4418–4424, 1976.
Sirotnak F. M., Donsbach R. C., Moccio D. M., Dorick D. M.: Biochemical and pharmacokinetic effects of leucovorin after high dose methotrexate in a murine leukaemia model. Cancer Res (36): 4679–4686, 1976.
Tattersall M. H. N., Harrap K. R.: Combination chemotherapy: the antagonism of methotrexate and cytosine arabinoside. Europ J Cancer (9): 229–232, 1973.
Tattersall M. H. N., Jackson R. C., Connors T. A., Harrap K. R.: Combination chemotherapy: the interaction of methotrexate and 5-fluorouracil. Europ J Cancer (9): 733–739, 1973.
Capizzi R. L., Nichols R., Mullins J.: Long term survival of leukemic mice by therapeutic synergism between asparaginase and methotrexate. Fed Proc (31): 553, 1972.
Tattersall M. H. N, Brown B., Frei E.: The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects. Nature (253): 198–200, 1975.
Grindey G. B., Seman J. H., Pavelic Z. P.: Modulation versus rescue of antimetabolite toxicity by salvage metabolites administered by continuous infusion. Antibiot Chemother (23): 295–304, 1978.
Howell S. B., Herbst K., Boss G. R., Frei E.: Thymidine requirements for the rescue of patients treated with high dose methotrexate. Cancer Res (40): 1824–1829, 1980.
Ensminger W. D., Frei E.: The prevention of methotrexate toxicity by thymidine infusions in humans. Cancer Res (37): 1857–1863, 1977.
Howell S. B., Mansfield S. J., Taetle R.: Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity. Cancer Res (40): 1824–1829, 1980.
Cadman Ed., Heimer R., Benz C.: The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chera (256): 1695–1704, 1980.
Fernandes D. J., Bertino J. R.: 5-Fluorouracil-methotrexate synergy. Enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proc Natl Acad Sci (77): 5663–5667, 1980.
Cadman E. D., Eiferman F.: Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside. Study of L1210 and human leukemic cells. J Clin Invest (64): 788–798, 1979.
Tattersall M. H. N., Jackson R. C., Jackson S. T. M., Harrap K. R.: Factors determining cell sensitivity to methotrexate: sudies of folate and deoxyribonucleoside triphosphate pools in 5 mammalian cell lines. Europ J Cancer (10): 818–826, 1974.
Harrap K. R., Taylor G. A., Browman G. P.: Enhancement of the therapeutic effectiveness of methotrexate and protection of normal tissues with purines and pyrimidines. Chem-Biol Interactions (18): 119–128, 1977.
Schornagel J. H., Leyva A., Pinedo H. M.: Is there a role for thymidine in cancer chemotherapy. Cancer Treat Rev (9): 331–352, 1982.
Taylor I. W., Tattersall M. H. N.: Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometry. Cancer Res (41): 1549–1558, 1981.
Taylor I. W., Slowiaczek P., Francis P. R., Tattersall M. H. N.: Biochemical and cell cycle perturbations in methotrexate-treated cells. Mol Pharmacol (21): 201–210, 1982.
Taylor I. W., Slowiaczek P. F., Francis P. R., Tattersall M. H. N.: Purine modulation of methotrexate cytotoxicity in mammalian cells. Cancer Res (42): 5159–5164, 1982.
Holden L., Hoffbrand A. V., Tattersall M. H. N.: Thymidine concentrations in human sera: variations in patients with leukaemia and megalaoblastic anaemia. Europ J Cancer (16): 115–120, 1980.
Tattersall M. H. N., Slowiazczek P., De Fazio A.: Regional variation on human extracellular purine levels. J Lab Clin Med (102): 411–420, 1983.
Bertino J. R., Sawicki W. L., Lindquist C. A., Gupa V. S.: Schedule dependent antitumour effects of methotrexate and 5-fluorouracil. Cancer Res (37): 327–328, 1977.
Mulder J. H., Smink T., Van Putten L. M.: 5-Fluorouracil and methotrexate combination chemotherapy: the effects of drug scheduling. Europ J Cancer (17): 831–838, 1981.
Piper A. A., Nott S. E., MacKinnon W. B., Tattersall M. H. N.: Critical modulation by thymidine and hypoxanthine of the sequential methotrexate-5-fluorouracil synergism in murine L1210 cells. Cancer Res (43): 5701–5705, 1983.
Coates A. S, Tattersall M. H. N., Slowiaczek P., Swanson C., Hedley D., Fox R. M., Raghavan D.: Sequential versus reversed methotrexate and 5-fluorouracil. A prospective randomized clinical trial of order of administration. J Clin Oncolol, 1983 (in press).
Editor information
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Tattersall, M.H.N. (1984). Antimetabolite Combinations Possessing Enhanced Efficacy. In: Harrap, K.R., Davis, W., Calvert, A.H. (eds) Cancer Chemotherapy and Selective Drug Development. Developments in Oncology, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3837-6_3
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3837-6_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3839-0
Online ISBN: 978-1-4613-3837-6
eBook Packages: Springer Book Archive